Evaxion A/S
$4.49
▲
3.28%
2026-04-21 06:43:01
evaxion.ai
NCM: EVAX
Explore Evaxion A/S stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$37.11 M
Current Price
$4.49
52W High / Low
$12.15 / $1.25
Stock P/E
—
Book Value
$2.04
Dividend Yield
—
ROCE
-38.23%
ROE
-1%
Face Value
—
EPS
$-1
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
46
Beta
0.2
Debt / Equity
44.04
Current Ratio
5.85
Quick Ratio
5.85
Forward P/E
101
Price / Sales
4.48
Enterprise Value
$1.67 B
EV / EBITDA
-188.1
EV / Revenue
221.71
Rating
None
Target Price
$11.25
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | CervoMed Inc. | $3.97 | — | $36.76 M | — | -155.27% | -93.92% | $13.13 / $3.51 | $1.97 |
| 2. | Catalyst Pharmaceuticals, Inc. | $26.07 | 14.85 | $3.18 B | — | 26.94% | 25.49% | $26.58 / $19.05 | $7.79 |
| 3. | MediWound Ltd. | $17.35 | — | $226.34 M | — | -41.75% | -63.86% | $22.5 / $14.9 | $3.4 |
| 4. | Cartesian Therapeutics, Inc. | $6.94 | — | $183.97 M | — | -30.8% | 195.88% | $15.57 / $5.6 | $-4.85 |
| 5. | Summit Therapeutics Inc. | $24.32 | — | $18.91 B | — | -161.37% | -2.06% | $36.91 / $13.83 | $0.85 |
| 6. | Cue Biopharma, Inc. | $0.85 | — | $82.97 M | — | -92.35% | -121.11% | $1.03 / $0.17 | $0.27 |
| 7. | Grace Therapeutics, Inc. | $4.59 | — | $71.03 M | — | -23.81% | -10.22% | $5.18 / $2 | $4.19 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 7.49 M | 0.04 M | 0 M | 0.12 M |
| Operating Profit | -4.05 M | 3.02 M | -4.34 M | -3.87 M | -4.02 M |
| Net Profit | -5.92 M | 4.62 M | -4.83 M | -1.58 M | -3.63 M |
| EPS in Rs | -0.71 | 0.55 | -0.58 | -0.19 | -0.44 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 7.53 M | 3.34 M | 0.07 M | 0 M |
| Operating Profit | -9.23 M | -14.73 M | -22.2 M | -25.26 M |
| Net Profit | -7.71 M | -10.57 M | -22.12 M | -23.17 M |
| EPS in Rs | -0.92 | -1.27 | -2.65 | -2.78 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 28.41 M | 12.48 M | 12.89 M | 22.02 M |
| Total Liabilities | 11.37 M | 14.14 M | 17.62 M | 13.72 M |
| Equity | 17.04 M | -1.65 M | -4.73 M | 8.3 M |
| Current Assets | 24.9 M | 8.77 M | 8.35 M | 16.98 M |
| Current Liabilities | 4.26 M | 4.37 M | 7.08 M | 3.76 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -6.62 M | -12.94 M | -17.69 M | -25.77 M |
| Investing CF | -0.01 M | -0 M | -0.09 M | -0.27 M |
| Financing CF | 22.41 M | 13.13 M | 10.69 M | 7.85 M |
| Free CF | -6.64 M | -12.94 M | -17.78 M | -26.07 M |
| Capex | -0.01 M | — | -0.09 M | -0.29 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 4480.82% | — | — | — |
| Earnings Growth % | 52.24% | 4.51% | — | — |
| Profit Margin % | -316% | -30308.22% | — | — |
| Operating Margin % | -440.55% | -30406.85% | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -292.64% | -29319.18% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-01-14 | 1:0.2 |
| 2024-01-22 | 1:0.1 |